Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ORGANIZATION
ORGANIZATION
- Diovan Issue is “Isolated Example,” Confidence in Japan Clinical Trials Not Lost: President Viehbacher of EFPIA
October 7, 2013
- JPMA Suspends Membership of Novartis Pharma in Response to Diovan Scandal
October 4, 2013
- JPMA Compliance Committee to Decide Penalties for Novartis for Diovan Case as Requested by Dr Teshirogi
October 3, 2013
- JGA Tells Members to Use Unified Trade Name “Losarhyd” for Generic Version of Combination Drug Preminent
October 1, 2013
- Generic Share Increases to 26.6% on Volume Basis in April-June 2013: JGA
October 1, 2013
- JSGM to Propose Incentive Dispensing Fee for Pharmacies That Carry Cheaper Generics, Unification of Premiums for Generic Dispensing Systems
September 26, 2013
- Japan, US Should Promote High Standards for Intellectual Property Protection and Pricing Transparency in TPP: PhRMA Executives
September 24, 2013
- JPMA Senior Managing Director Hiroaki Nakatani to Retire
September 17, 2013
- Transparency Guidelines: JPMA Says Requested Viewers’ Names, Affiliations Could Be Checked before Disclosing Individual Payment Information
September 13, 2013
- Wholesale Industry FTC Calls for Freeze on Efforts by Wholesalers to Refuse Free Services to Customers Due to Sharp Reactions from Some Pharmacies
September 4, 2013
- Min-Iren to Suspend Use of Diovan at 143 Member Hospitals
August 30, 2013
- JMA, PhRMA to Cosponsor Symposium on National Health Insurance System in September
August 29, 2013
- Insulin Treatment Improves Patients’ QOL, Marital Relationship: Healthy Japan 21 Promotion Forum, Sanofi
August 23, 2013
- Stakeholders Should Discuss Novartis’ Responsibility in the Promotion of Diovan, Large Sales: JMA Vice President
August 19, 2013
- Japanese Wholesalers Fill Role of Social Infrastructure: JPWA Report
August 14, 2013
- JMA Establishes Pharmaceutical Affairs Section to Strengthen Engagement with Generic Drug and Distribution Issues
August 9, 2013
- Kenporen Report Recommends Reference to Measures Taken in UK, France to Further Promote Use of Generics in Japan
August 7, 2013
- ICH to Facilitate Participation of Regulatory Authorities from Non-ICH Regions in Future Activities
July 30, 2013
- Average Cost of Domestic Development Was 48.4 Billion Yen per Drug from 2000-2008: OPIR
July 29, 2013
- Red Cross Hospitals to Share Information on Drug Discount Rates
July 29, 2013
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…